Full Text Available

Note: Clicking the button above will open the full text document at the original institutional repository in a new window.

LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154)

Saved in:
Bibliographic Details
Published in:Lung Cancer: Targets and Therapy
Format: Online Article RSS Article
Published: 2025
Subjects:
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1867301672329412614
collection WordPress RSS
FRELIP Feed Integration
container_title Lung Cancer: Targets and Therapy
description
discipline_display Respiratory Diseases
discipline_facet Respiratory Diseases
format Online Article
RSS Article
genre Journal Article
id rss_article:58427
institution FRELIP
journal_source_facet Lung Cancer: Targets and Therapy
publishDate 2025
publishDateSort 2025
record_format rss_article
spellingShingle LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154)
Respiratory Diseases
General
Respiratory Diseases
sub_discipline_display General
sub_discipline_facet General
subject_display Respiratory Diseases
General
Respiratory Diseases
Respiratory Diseases
General
Respiratory Diseases
subject_facet Respiratory Diseases
General
Respiratory Diseases
title LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154)
title_auth LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154)
title_full LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154)
title_fullStr LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154)
title_full_unstemmed LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154)
title_short LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154)
title_sort laura completes the osimertinib treatment jigsaw puzzle of egfr+ nsclc from stage ib to iv: adjuvant osimertinib significantly improves pfs and cns progression in unresectable stage iii egfr-mutated nsclc compared to placebo (laura, nct03521154)
topic Respiratory Diseases
General
Respiratory Diseases
url https://www.dovepress.com/laura-completes-the-osimertinib-treatment-jigsaw-puzzle-of-egfr-nsclc--peer-reviewed-fulltext-article-LCTT